Positive Safety Data for EyePoint Pharmaceuticals' Lead Product Candidate

October 1, 2021

EyePoint Pharmaceuticals saw a 13% increase in its shares, reaching $11.60, following the release of positive interim safety data for its lead product candidate, EYP-1901. The data was obtained from a Phase 2 trial.

The trial evaluated EYP-1901 as a potential nine-month treatment for moderately-severe to severe non-proliferative diabetic retinopathy and as a potential six-month sustained delivery maintenance treatment for wet age-related macular degeneration.

As of September 1, all treatment arms in the trial have completed at least three months of follow-up post-dosing. During the ongoing Phase 2 trial, a total of 170 patients have received EYP-1901 with a minimum of three months of follow-up post injection. No severe adverse drug-related ocular events or systemic effects have been reported.

EyePoint remains on track to release topline results from the trial in December.

The primary efficacy endpoint of the trial is improvement of at least two levels on the diabetic retinopathy severity scale by week 36 after the EYP-1901 injection. Secondary endpoints include reducing vision-threatening complications, occurrence of diabetic macular edema and/or proliferative disease, retinal ischemia/nonperfusion, and safety.